ImmunoAct, backed by government funding, is advancing CAR-T cell therapy to make cancer treatment more accessible. Their product, NexCAR19, uses patients' immune systems to fight cancer. With support ...

Our results suggest that patients who are considering lentiviral vector gene therapy should continue to be educated on the risk of hematologic cancer and, if treated, monitored closely.

Through studies that were amongst the largest of their kind, we identified several genes involved in breast and/or ovarian cancer predisposition such as CHEK2, BRIP1, ATM, PALB2, RAD51C and RAD51D.

Some gene therapy treatments use modified adeno-associated viruses (AAVs) like the one shown here to deliver therapeutic genetic material into a patient’s cells. In a finding with implications for one ...

A research team has made a major discovery on how the CUL5 gene affects CAR-T cell therapy, an advanced cancer therapy. The study reveals that reducing the activity of the CUL5 gene helps CAR-T cells ...

Scientists looked at multiple techniques used to measure the modified viruses deployed in some gene therapy research and treatments. One technique, known as SEC-MALS, was the most precise and accurate ...

Akamis Bio, a clinical-stage oncology company, has raised $60 million in Series A funding that will drive continued development of NG-350A, a new gene therapy based on its proprietary tumor-specific ...

After telegraphing an investigation in November, the FDA has moved to restrict the use of bluebird bio’s gene therapy Skysona in certain patients. The FDA has updated Skysona’s indication, allowing it ...

The government has extended financial support to ImmunoAct to expand gene delivery systems, making breakthrough cancer treatments more affordable. Clinical trials of CAR-T therapy have been promising ...

This story is part of a series on the current progression in Regenerative Medicine. In 1999, I defined regenerative medicine as the collection of interventions that restore tissues and organs damaged ...